WuXi PharmaTech borrows to expand
February 24, 2015Manufacturing and Production, Sales and Marketing China, NextCODE Health, WuXi PharmaTech, XenoBiotic Laboratories, philadelphia
WuXi PharmaTech has kick started a syndicated loan arrangement in order to borrow up to $165 million from a consortium …
Algatech gets new chief executive and chief scientist
February 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Algatech, Ronnie Meninger, Sammy Boussiba
Israel-based biotech Algatech has confirmed the appointment of Ronnie Meninger as its chief executive, and Sammy Boussiba as chief scientist. Meninger (pictured) …
Merck invests $450m in NGM Biopharma
February 23, 2015Sales and Marketing Merck, NGM Biopharma, NP201, diabetes, nonalcoholic steatohepatitis, obesity
Merck is to collaborate on drug development with biotech firm NGM Pharmaceuticals in a $450 million deal. The collaboration will …
Priority review for Pfizer’s lung drug
February 23, 2015Sales and Marketing FDA, Pfizer, Rapamune, lung, lymphangioleiomyomatosis, sirolimus
The US Food and Drug Administration FDA has accepted Pfizer’s lung drug Rapamune for priority review. Rapamune (sirolimus) prevents organ …
Chiesi’s stem cell therapy approved in Europe
February 23, 2015Research and Development, Sales and Marketing Chiesi, EC, Europe, Holoclar, Holostem Advanced Therapies, LSCD, stem cell
Chiesi’s Holoclar has become the first stem cell therapy to get the green light in Europe, gaining conditional approval from …
UK government spends £300 million on dementia
February 23, 2015Research and Development, Sales and Marketing Cameron, England, NHS, dementia, investment, research
UK prime minister David Cameron has said the government is to invest more than £300m into dementia research and that …
Valeant to buy Salix in $14.5 billion move
February 23, 2015Sales and Marketing Deals, Heptares, Valeant, mergers, salix, sosei
Valeant has agreed a deal to acquire US-based speciality manufacturer of gastrointestinal drugs Salix in a move worth around $14.5 …
Act now – or risk running out of time for IDMP
February 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Eversheds, ISO, icsr, idmp, regulatory
Many people in pharma would argue that the world of regulatory compliance in the life sciences industry is already complicated …
Kymab hires chief financial officer
February 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing anne hyland, kymab
Cambridge-based UK antibody development firm Kymab has appointed Anne Hyland as its chief financial officer. Hyland takes to the firm …
Boehringer’s beer breach at German congress
February 20, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, ERS, IPF, PMCPA, breach, code, munich
A complaint made by a pulmonologist against the competence of Boehringer Ingelheim speakers during a congress held in Germany last …
Chair appointed for new MHRA devices committee
February 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MHRA, Peter Nightingale, deac
Dr Peter Nightingale has been appointed as chairman of the Medicines and Healthcare products Regulatory Agency’s (MHRA) newly-formed Devices Expert …
Resistance threat to malaria drug is ‘alarming’
February 20, 2015Research and Development, Sales and Marketing Africa, Qinghaosu, artemisinin, malaria, thailand
Resistance to a group of drugs that possess the most rapid action against malaria – artemisinin, aka Qinghaosu – is …
Official linked to GSK bribes facing prison
February 20, 2015Sales and Marketing China, Deirdre Connelly, GSK, Jack Bailey, Novartis, bribes
A Chinese health official linked to the GSK bribery scandal has been sentenced to 19 years in prison. Huang Fenping, …
Sanofi confirms new chief executive
February 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Chris Viehbacher, Sanofi, praluent
Bayer chairman Olivier Brandicourt has been named as Sanofi’s new chief executive to replace Chris Viehbacher who was ejected from …
NICE is ‘setting prices too high’ for NHS
February 19, 2015Sales and Marketing ABPI, NHS, NICE, QALY, costs, health, pharma
The cost threshold NICE uses when approving drugs is too high and is doing more harm than good, new research …
Celgene gets FDA licence extension for myeloma drug
February 19, 2015Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma
The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …
Pharming names new chief scientific officer
February 19, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharming, perry calais
Dutch biopharma development firm Pharming has named Dr Perry Calias as the company’s chief scientific officer. Calias will have overall …
UK pharma commits at least ‘one code breach a week’
February 18, 2015Medical Communications, Sales and Marketing ABPI, AstraZeneca, Bayer, Eli Lilly, GSK, Novartis, Novo Nordisk, PMCPA, Pfizer, code
Pharma companies commit unethical marketing practices on average more than once a week in the UK academic analysis has found. …
Sanofi enters autoimmune diseases pact with Lead Pharma
February 18, 2015Research and Development, Sales and Marketing Sanofi, autoimmune, biox, lead pharma, psoriasis
Sanofi is to collaborate with Dutch biotech firm Lead Pharma to develop treatments for autoimmune diseases. The companies will work …
£30m drug discovery centres launched to overcome pharma ‘funding fatigue’
February 18, 2015Research and Development, Sales and Marketing Alzheimer’s Research UK, Cambridge, London, Oxford, dementia, funding, pharma
Three new drug discovery institutes will be launched in the UK with a £30 million commitment to fast-track the development …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
